LYMErix Product Liability Suit Seeks Testing For OspA Sensitivity
• By The Pink Sheet
A product liability lawsuit is arguing that SmithKline Beecham's LYMErix vaccine should be used only in patients that have been tested for sensitivity to the outer surface protein A Lyme disease vaccine.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.